NIH Study Will Reduce Immunosuppressive Medication Before, After Extra Vaccine Dose

January 31, 2022

A study has begun to assess the antibody response to an additional dose of a COVID-19 mRNA vaccine in kidney and liver transplant recipients, either alone or with a concurrent reduction in immunosuppressive medication. The clinical trial will enroll people for whom two to four doses of a COVID-19 mRNA vaccine did not elicit a detectable antibody response. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring and funding the Phase 2 trial, called COVID Protection After Transplant–Immunosuppression Reduction, or CPAT-ISR.

“Eliciting a protective immune response to COVID-19 vaccines in some organ transplant recipients continues to be a challenge,” said NIAID Director Anthony S. Fauci, M.D. “We are concerned about protecting everyone from COVID-19 and therefore continue to develop and test new approaches to make vaccination effective for all organ transplant recipients.” (continue)

https://www.niaid.nih.gov/news-events/nih-launches-study-third-covid-19-vaccine-dose-kidney-transplant-recipients

COVID Protection After Transplant-Immunosuppression Reduction (CPAT-ISR)

COVID-19 Protection After Transplant Pilot Study (CPAT)